Executive Summary

Histological evaluation in non-human primate (NHP) models provides the definitive assessment of an AAV vector’s safety profile, directly informing its clinical viability. The primary challenge is interpreting complex cellular responses to distinguish between transient, mechanism-related inflammation and adverse findings that pose a risk to the program. A successful IND-enabling toxicology study depends on expert pathological interpretation that correlates tissue-level findings with vector design, administration route, and other key study endpoints within a GxP framework.

Interpreting Immune Response in IND-Enabling Studies

The interpretation of immune-mediated findings from NHP histology is a key decision point in AAV therapeutic development. A nuanced understanding is required to differentiate between anticipated, self-limiting inflammatory responses and unexpected toxicities that could delay or terminate a program. Our teams operate within a >100,000 sq ft facility designed to support these complex studies, contributing to a typical 18-24 month IND timeline.

The molecular structure of the vector genome itself can influence tissue response. Research shows that heterogeneity in vector genome structures within large animal models can impact transduction efficiency and persistence, which in turn may affect the nature of the local cellular response (PMID: 20113166). This highlights the need for meticulous histological correlation. Key vector design elements that warrant careful pathological assessment include:

• Capsid Serotype: Different serotypes exhibit distinct tissue tropisms and immunogenic profiles.

• Promoter Selection: The choice of promoter can drive transgene expression in specific cell types, potentially leading to on-target or non-target tissue effects.

• Genome Configuration: Self-complementary or single-stranded AAV designs have different expression kinetics that can influence the host immune response.

The Impact of Administration Route on Histological Outcomes

The route of administration is a primary determinant of histological findings. Systemic versus localized delivery results in vastly different biodistribution profiles and potential for immune activation. Studies evaluating intrathecal AAV delivery, for example, have demonstrated that different administration techniques can provoke significant inflammatory events even when achieving similar transduction levels (PMID: 28806897). This work underscores that a vector safe for one application may present unforeseen challenges with another, demanding route-specific pathological evaluation.

Our GxP-compliant histology services are designed to identify and characterize these route-dependent effects. This approach provides rapid pathology insights accelerating preclinical readouts and delivers clear data for regulatory submissions.

)

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner